Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: Regional and receptor specificity

Neuroscience

Volumn 74, Issue 3, 1996, Pages 793-804

  You, Z B ^a   Herrera Marschitz, M ^a   Pettersson, E ^a   Nylander, I ^a   Goiny, M ^a   Shou, H Z ^a   Kehr, J ^a   Godukhin, O ^a   Hokfelt T ^a   Terenius, L ^a   Ungerstedt, U ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Amino acids; Cholecystokinin; Dopamine; Dynorphin; Microdialysis; Rat

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 AMINOBUTYRIC ACID; ASPARTIC ACID; CHOLECYSTOKININ OCTAPEPTIDE; DEVAZEPIDE; DOPAMINE; DYNORPHIN B; GLUTAMIC ACID; OXIDOPAMINE; TETRAGASTRIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; MICRODIALYSIS; NEOSTRIATUM; NONHUMAN; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

EID: 0030564974     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(96)00149-2     Document Type: Article

References (76)

1. Barnes S., Whistler H. L., Hughes J., Woodruff G. N., Hunter J. C. Effect of cholecystokinin octapeptide on endogenous amino acid release from the rat ventromedial nucleus of the hypothalamus and striatum. J. Neurochem. 56:1991;1409-1416.
2. Beresford I. J. M., Hall M. D., Clark C. R., Hill R. J., Sirinathsinghi D. J. S. Striatal lesions and transplants demonstrate that CCK receptors are localized on intrinsic striatal neurones: a quantitative autoradiographic study. Neuropeptides. 10:1987;109-136.
3. Bock M. G., DiPardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Veber D. F., Anderson P. S., Freidinger R. M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands L-365,260. J. med. Chem. 32:1989;13-16.
4. Bunney B. S., Aghajanian G. K. The precise localization of nigral afferents in the rat as determined by a retrograde tracing technique. Brain Res. 117:1976;423-435.
5. Burgunder J.-M., Young W. S. Cortical neurons expressing the cholecystokinin gene in the rat: distribution in the adult brain, ontogeny, and some of their projections. J. comp. Neurol. 300:1990;26-46.
6. Butcher S. P., Varro A., Kelly J. S., Dockray G. J. In vivo studies on the enhancement of cholecystokinin release in the rat striatum by dopamine depletion. Brain Res. 505:1989;119-122.
7. Chang R. S. L., Lotti V. J. Biochemical and pharmacological characterization of an extremely potent and selective non-peptide cholecystokinin antagonist. Proc. natn. Acad. Sci. U.S.A. 83:1986;4923-4926.
8. Christensson-Nylander I., Herrera-Marschitz M., Staines W., Hökfelt T., Terenius K., Ungerstedt U., Cuello C., Oertel W. H., Goldstein M. Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical evidence. Expl Brain Res. 64:1986;169-192.
9. Crawley J. N. Cholecystokinin-dopamine interactions. Trends pharmac. Sci. 12:1991;232-236.
10. Dockray G. J. Cholecystokinin in rat cerebral cortex: identification, purification and characterization by immunochemical methods. Brain Res. 188:1980;155-165.
11. Dodd P. R., Edwarson J. A., Dockray G. L. The depolarisation-induced release of CCK-terminal octapeptide (CCK-8) from rat synaptosomes and brain slices. Regul. Pept. 1:1980;17-29.
12. Druce D., Peterson D., De Belleroche J., Bradford H. F. Differential amino acid neurotransmitter release in rat neostriatum following lesioning of the cortico-striatal pathway. Brain Res. 247:1982;303-307.
13. Emson P. C., Rehfeld J. F., Langevin H., Rossor M. N. Reduction in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington's disease. Brain Res. 198:1980;497-500.
14. Evans B. E., Bock M. G., Rittle K. E., DiPardo R. M., Whitter W. L., Veber D. F., Anderson P. S., Freidinger R. M. Design of potent, orally effective, non-peptide antagonists of the peptide hormone cholecystokinin. Proc. natn. Acad. Sci. U.S.A. 83:1986;4918-4922.
15. Fallon J. H., Leslie F. M. Distribution of dynorphin and enkephalin peptides in the brain. J. comp. Neurol. 249:1986;293-336.
16. Fonnum F., Storm-Mathisen J., Divac I. Biochemical evidence for glutamate as neurotransmitter in the cortico-striatal and cortico-thalamic fibres in rat brain. Neuroscience. 6:1981;863-875.
17. Gaudreau P., Quirion R., St. Pierre S., Chieuh C. C., Pert A. Localization of CCK receptors in relation to the nigro-striatal and mesolimbic dopaminergic pathways. Neuropeptides. 9:1987;283-293.
18. Gerfen C. R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. A. Rev. Neurosci. 15:1992;285-320.
19. Girault J. A., Barbeito L., Spampinato U., Gozlan H., Glowinski J., Besson M.-J. In vivo release of endogenous amino acids from the rat striatum: further evidence for a role of glutamate and aspartate in corticostriatal neurotransmission. J. Neurochem. 47:1986;98-106.
20. 3H]γ-aminobutyric acid in the rat neostriatum - II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen. Neuroscience. 19:1986;1109-1117.
21. 3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Neurosci. Lett. 131:1991;129-134.
22. Grofova I., Deniau J. M., Kitai S. T. Morphology of substantia nigra pars reticulata projection neurons intracellularly labelled with HRP. J. comp. Neurol. 298:1982;352-368.
23. Hammond C., Deniau J. M., Rizk A., Feger J. Electrophysiological demonstration of an excitatory subthalamo-nigral pathway in the rat. Brain Res. 151:1978;235-244.
24. Herrera-Marschitz M., Ungerstedt U. Evidence that striatal efferents relate to different dopamine receptors. Brain Res. 323:1984;269-278.
25. Herrera-Marschitz M., Meana J. J., O'Connor W. T., Goiny M., Reid M. S., Ungerstedt U. Neuronal dependence of extracellular dopamine, acetylcholine, glutamate, aspartate and gamma-aminobutyric acid (GABA) measured simultaneously from rat neostriatum using in vivo microdialysis: reciprocal interactions. Amino Acids. 2:1992;157-179.
26. Herrera-Marschitz M., Meana J. J., Hökfelt T., You Z.-B., Morino P., Brodin E., Ungerstedt U. Cholecystokinin is released from a crossed corticostriatal pathway. NeuroReport. 3:1992;905-908.
27. Herrera-Marschitz M., You Z.-B., Goiny M., Meana J. J., Slveira R., Godikhin O. V., Chen Y., Espinoza S., Pettersson E., Loidl C. F., Lubec G., Andersson K., Nylander I., Terenius L., Ungerstedt U. On the origin of extracellular glutamate levels monitored in the basal ganglia of the rat by in vivo microdialysis. J. Neurochem. 66:1996;1726-1735.
28. Heyden J. A. M. van der, Venema K., Korf J. In vivo release of endogenous GABA from rat striatum: inhibition by dopamine. J. Neurochem. 34:1980;1338-1341.
29. Hill D. R., Campbell N. J., Shaw T. M., Woodruff G. N. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J. Neurosci. 7:1987;2967-2977.
30. 3H-MK-329. J. Neurosci. 10:1990;1070-1081.
31. Hökfelt T., Skirboll L., Rehfeld J. F., Goldstein M., Markey K., Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience. 5:1980;2093-2124.
32. Hökfelt T., Herrera-Marschitz M., Seroogy K., Ju G., Staines W. A., Holets V., Schalling M., Ungerstedt U., Post C., Rehfeld J. F., Frey P., Fischer J., Dockray G. J., Hamaoka T., Walsh J. H., Goldstein M. Immunohistochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence specific antisera and with special reference to the caudate nucleus and primary sensory neurons. J. chem. Neuroanat. 1:1988;11-52.
33. Hommer D., Stoner G., Crawley J., Paul S., Skirboll L. CCK-dopamine coexistence: electrophysiological actions corresponding to CCK receptor subtype. J. Neurosci. 6:1986;3039-3043.
34. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., Woodruff G. N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. natn. Acad. Sci. U.S.A. 87:1990;6728-6732.
35. Innis R. B., Snyder S. Distinct cholecystokinin receptors in brain and pancreas. Proc. natn. Acad. Sci. U.S.A. 77:1980;6917-6921.
36. Kehr J. (1994) Determination of GABA in microdialysis samples by microbore HPLC and fluorescence detection. Application Notes, Vol. 19. CMA/Microdialysis AB, Stockholm.
37. Khachaturian H., Watson S. J., Lewis M. E., Coy D., Goldstein A., Akil H. Dynorphin immunocytochemistry in the rat central nervous system. Peptides. 3:1982;941-954.
38. Kita H., Kitai S. T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. comp. Neurol. 260:1987;435-452.
39. Larsson L.-I., Rehfeld J. Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res. 165:1979;201-218.
40. Lindefors N., Brodin E., Tossman U., Segovia J., Ungerstedt U. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Expl Brain Res. 74:1989;527-534.
41. B) ligand: L-365,260. Eur. J. Pharmac. 162:1989;273-280.
42. Maidment N. T., Siddall B. J., Rudolph V. D., Erdelyi E., Evans C. J. Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: microdialysis combined with a sequential multiple antigen radioimmunoassay. Neuroscience. 45:1991;81-93.
43. Meana J. J., Herrera-Marschitz M., Brodin E., Hökfelt T., Ungerstedt U. Simultaneous determination of cholecystokinin, dopamine, glutamate and aspartate in cortex and striatum of the rat using in vivo microdialysis. Amino Acids. 1:1991;365-373.
44. Meyer D. K., Beinfeld M. C., Oertel W. H., Brownstein M. J. Origin of the cholecystokinin containing fibers in the caudate-putamen. Science. 215:1982;187-188.
45. Meyer D. K., Protopapas Z. Studies on cholecystokinin-containing neuronal pathways in rat cerebral cortex and striatum. Ann. N. Y. Acad. Sci. 448:1985;133-143.
46. Meyer D. K., Schultheiss K., Hardung M. Bilateral ablation of frontal cortex reduces concentration of cholecystokinin-like immunoreactivity in rat dorsolateral striatum. Brain Res. 452:1988;113-117.
47. Morino P., Herrera-Marschitz M., Meana J. J., Ungerstedt U., Hökfelt T. Immunohistochemical evidence for a crossed cholecystokinin corticostriatal pathway in the rat. Neurosci. Lett. 148:1992;133-136.
48. Morino P., Herrera-Marschitz M., Castel M. N., Ungerstedt U., Varro A., Dockray G., Hökfelt T. Cholecystokinin in cortico-striatal neurons in the rat: immunohistochemical studies at the light and electron microscopical level. Eur. J. Neurosci. 6:1994;681-692.
49. Naito A., Kita H. The cortico-nigral projection in the rat: an anterograde tracing study with biotinylated dextran amine. Brain Res. 637:1994;317-322.
50. Narahashi T. Chemical tools in the study of excitable membranes. Physiol. Rev. 54:1974;813-889.
51. Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates, pp. 1-145. Academic Press, New York.
52. 3H]γ-aminobutyric acid release in slices from various brain areas. Eur. J. Pharmac. 250:1993;423-430.
53. 1-subtype of receptor. Neuroscience. 74:1996;51-66.
54. Reid M., O'Connor W. T., Herrera-Marschitz M., Ungerstedt U. Intranigral GABA and dynorphin A injections modulate striatal dopamine and GABA levels: evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 receptors. Brain Res. 519:1990;255-260.
55. Saito A. H., Sankaran H., Goldine I. D., Williams J. A. Cholecystokinin receptors in the brain: characterization and distribution. Science. 208:1980;1155-1156.
56. Sandberg M., Ward H. K., Bradford H. F. Effect of cortico-striatal pathway lesion on the activities of enzymes involved in synthesis and metabolism of amino acid neurotransmitters in the striatum. J. Neurochem. 44:1985;42-47.
57. Schiffmann S. N., Vanderhaeghen J.-J. Lesion of the nigrostriatal pathway induces cholecystokinin messenger RNA expression in the striatum. An in situ hybridization histochemistry study. Neuroscience. 50:1992;551-557.
58. Seroogy K. B., Dangaran K., Lim S., Haycook J. W., Fallon J. H. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J. comp. Neurol. 279:1989;397-414.
59. Skirboll L. R., Grace A. A., Hommer D. W., Rehfeld J., Goldstein M., Hökfelt T., Bunney B. S. Peptide-monoamine coexistence: studies on the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience. 6:1981;2111-2124.
60. Smith A. D., Bolam J. P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci. 13:1990;259-265.
61. Snyder G. L., Fisone G., Morino P., Gundersen V., Ottersen O. P., Hökfelt T., Greengard P. Regulation by the neuropeptide cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatum. Proc. natn. Acad. Sci. U.S.A. 90:1993;11277-11281.
62. Takagi H., Mizuta H., Matsuda T., Inagaki S., Tateishi K., Hamaoka T. The occurrence of cholecystokinin-like immunoreactive neurons in the rat neostriatum: light and electron microscopic analysis. Brain Res. 309:1984;346-349.
63. Ungerstedt U., Herrera-Marschitz M., Jungnelius U., Ståhle L., Tossman U., Zetterström T. Dopamine synaptic mechanisms reflected in studies combining behavioural recordings and brain dialysis. Adv. Biosci. 37:1982;219-231.
64. Vanderhaeghen J. J., Signeau J. C., Gepts W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature. 257:1975;604-605.
65. 3H-cholecystokinin as radioligand. J. Neurosci. 4:1984;1021-1033.
66. Vincent S. R., Hökfelt T., Christensson I., Terenius L. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur. J. Pharmac. 85:1982;251-252.
67. Wank S. A., Harkins R., Jensen R., Shapira H., de Weerth A., Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc. natn. Acad. Sci. U.S.A. 89:1992;3125-3129.
68. Wank S. A., Pisegna I. R., de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc. natn. Acad. Sci. U.S.A. 89:1992;8691-8695.
69. White L. E., Hodges H. D., Carnes K. M., Price J. L., Dubinsky J. M. Co-localization of excitatory and inhibitory neurotransmitter markers in striatal projection neurons in the rat. J. comp. Neurol. 339:1994;328-340.
70. Woodruff G. N., Hill D. R., Boden P., Pinnock R., Singh L., Hughes J. Functional role of brain CCK receptors. Neuropeptides. 19(Suppl.):1991;45-56.
71. Wu T.-L., Wang H. CCK-8 excites substantia nigra dopaminergic neurons by increasing a cationic conductance. Neurosci. Lett. 170:1994;229-232.
72. You Z.-B., Herrera-Marschitz M., Brodin E., Meana J. J., Morino P., Hökfelt T., Silveira R., Goiny M., Ungerstedt U. On the origin of striatal cholecystokinin release: studies with in vivo microdialysis. J. Neurochem. 62:1994;76-85.
73. You Z.-B., Pettersson E., Herrera-Marschitz M., Hökfelt T., Terenius L., Nylander I., Goiny M., Hughes J., O'Connor W. T., Ungerstedt U. Modulation of striatal aspartate and dynorphin B release by cholecystokinin (CCK-8) studied in vivo with microdialysis. NeuroReport. 5:1994;2301-2304.
74. +-depolarization, lesions and peptidase inhibition. Neuroscience. 63:1994;415-425.
75. You Z.-B., Herrera-Marschitz M., Nylander I., O'Connor W. T., Goiny M., Ungerstedt U., Terenius L. The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis - II. Effects of dopamine D1 and D2 receptor agonists. Neuroscience. 63:1994;427-434.
76. You Z.-B., Herrera-Marschitz M., Nylander I., Goiny M., Kehr J., Ungerstedt U., Terenius L. Effect of morphine on dynorphin B and GABA release in the basal ganglia of rats. Brain Res. 710:1996;241-248.